Akt-directed metabolic alterations in cancer

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 2, 2005, Pages 255-262

  Hatzivassiliou, Georgia ^a   Andreadis, Charalambos ^b   Thompson, Craig B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; AMINO ACID; ANTINEOPLASTIC AGENT; AP 23573; CERULENIN; DEGUELIN; DEOXYGLUCOSE; EPIGALLOCATECHIN GALLATE; EVEROLIMUS; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUFOSFAMIDE; GROWTH FACTOR RECEPTOR; HEXOKINASE; HEXOKINASE ISOENZYME; HYDROXYCITRIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPID; PROTEIN BAD; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SRI 3668; TEMSIROLIMUS; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROBIC METABOLISM; AMINO ACID METABOLISM; BIOSYNTHESIS; CANCER; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME REGULATION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; NONHUMAN; NUTRIENT UPTAKE; PHENOTYPE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; WARBURG EFFECT;

EID: 33645054801     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.05.007     Document Type: Review

References (43)

1. R.N. Anderson B.L. Smith Deaths: Leading causes for 2002 Natl. Vital Stat. Rep. 53 2005 1-89
2. P.S. Hammerman et. al. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival Trends Biochem. Sci. 29 2004 586-592
3. E.L. Whiteman et. al. Role of Akt/protein kinase B in metabolism Trends Endocrinol. Metab. 13 2002 444-451
4. J.A. Fresno Vara et. al. PI3K/Akt signalling pathway and cancer Cancer Treat. Rev. 30 2004 193-204
5. D.R. Plas et. al. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology J. Biol. Chem. 276 2001 12041-12048
6. K. Gottlob et. al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase Genes Dev. 15 2001 1406-1418
7. J.C. Rathmell et. al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival Mol. Cell. Biol. 23 2003 7315-7328
8. N. Majewski et. al. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases Mol. Cell. Biol. 24 2004 730-740
9. R.L. Elstrom et. al. Akt stimulates aerobic glycolysis in cancer cells Cancer Res. 64 2004 3892-3899
10. M. Younes et. al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers Cancer Res. 56 1996 1164-1167
11. A.L. Edinger C.B. Thompson Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake Mol. Biol. Cell 13 2002 2276-2288
12. N. Majewski et. al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak Mol. Cell 16 2004 819-830
13. N.N. Danial et. al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis Nature 424 2003 952-956
14. P.K. Majumder et. al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat. Med. 10 2004 594-601
15. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 3 2003 721-732
16. A.M. Arsham et. al. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription J. Biol. Chem. 277 2002 15162-15170
17. A.M. Arsham et. al. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis Cancer Res. 64 2004 3500-3507
18. D. Accili K.C. Arden FoxOs at the crossroads of cellular metabolism, differentiation, and transformation Cell 117 2004 421-426
19. C. Wolfrum et. al. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes Nature 432 2004 1027-1032
20. S. Nemoto et. al. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway Science 306 2004 2105-2108
21. F.P. Kuhajda Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology Nutrition 16 2000 202-208
22. Buzzai, M. et al. (2005) The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid b-oxidation. Oncogene advance online publication, 4 April 2005; doi:10.1038/ sj.onc.1208622; http://www.nature.com/onc/index.html
23. M.A. Bjornsti P.J. Houghton The TOR pathway: A target for cancer therapy Nat. Rev. Cancer 4 2004 335-348
24. Y.A. Yang et. al. Activation of fatty acid synthesis during neoplastic transformation: Role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase Exp. Cell Res. 279 2002 80-90
25. T. Van de Sande et. al. Role of the phosphatidylinositol 3′-kinase/ PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells Cancer Res. 62 2002 642-646
26. C. Kumar-Sinha et. al. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis Cancer Res. 63 2003 132-139
27. A. Szutowicz et. al. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast Br. J. Cancer 39 1979 681-687
28. J. Turyn et. al. Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer Horm. Metab. Res. 35 2003 565-569
29. D.C. Berwick et. al. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes J. Biol. Chem. 277 2002 33895-33900
30. H.G. Wendel et. al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 18 2004 332
31. W.X. Zong et. al. Alkylating DNA damage stimulates a regulated form of necrotic cell death Genes Dev. 18 2004 1272-1282
32. K.H. Chun et. al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells J. Natl. Cancer Inst. 95 2003 291-302
33. L. Yang et. al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt Cancer Res. 64 2004 4394-4399
34. A.M. Martelli et. al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells Leukemia 17 2003 1794-1805
35. E.J. Meuillet et. al. Specific inhibition of the Akt1 pleckstrin homology domain by d -3-deoxy-phosphatidyl-myo-inositol analogues Mol. Cancer Ther. 2 2003 389-399
36. R.D. Rao et. al. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents Curr. Cancer Drug Targets 4 2004 621-635
37. T.R. Kau et. al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells Cancer Cell 4 2003 463-476
38. A.L. Kung et. al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway Cancer Cell 6 2004 33-43
39. R.H. Xu et. al. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia Cancer Res. 65 2005 613-621
40. G. Maschek et. al. 2-Deoxy- d -glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo Cancer Res. 64 2004 31-34
41. F.P. Kuhajda et. al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase Proc. Natl. Acad. Sci. USA 97 2000 3450-3454
42. K. Brusselmans et. al. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells Int. J. Cancer 106 2003 856-862
43. M. Board E. Newsholme Hydroxycitrate causes altered pyruvate metabolism by tumorigenic cells Biochem. Mol. Biol. Int. 40 1996 1047-1056